This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Founder Of Nestle-Acquired Company Joins Prismic Pharmaceuticals





SCOTTSDALE, Ariz., February 12, 2013 /PRNewswire/ -- Prismic Pharmaceuticals, Inc., a Scottsdale, Arizona-based pharmaceutical company focused on prescription Medical Foods, today announced that Danilo Casadei Massari, the founder of CM&D Pharma recently acquired by Nestle, has joined Prismic's Management Team and Board of Directors.

Casadei Massari, who has an outstanding reputation as a successful healthcare entrepreneur, becomes President Europe with additional responsibility for worldwide corporate development. He has also been elected to the company's Board of Directors.

Commenting on this significant development, Peter Moriarty, CEO and Chairman of the Board of Directors, stated, "Danilo has been involved in the founding and development of a number of very successful companies in the pharmaceutical and healthcare arenas. His venture prior to Prismic was CM&D Pharma, a European-based company also focused on prescription Medical Foods. CM&D Pharma was the first acquisition made by Nestle Health Science, a company established by Nestle in 2011 to create a new market between Food and Pharmaceuticals."

Danilo Casadei Massari added that "Prismic is developing an extremely interesting portfolio. These are all IP protected, science-based products that are safe and effective, and can be expeditiously brought to market as prescription Medical Foods. One or two of these are also being evaluated as potential NDA candidates based on clinical data we have seen so far. Our focus is on products that can cost-effectively address commonly occurring disorders in the aging "baby boomer" population, and especially those where inflammation is an underlying cause."

In summing-up, Peter Moriarty stated, "This is another major step-forward for Prismic, especially as we have also recently completed our initial round of equity funding which was significantly over-subscribed."

About Prismic Pharmaceuticals, Inc. Prismic Pharmaceuticals, Inc., is a privately held pharmaceutical company focused on the development and marketing of prescription medical foods for the clinical dietary management of the metabolic processes associated with many of the disorders associated with the aging population, particularly where inflammation is involved. The company, founded in 2011, is headquartered in Scottsdale, Arizona, with offices in Boston, USA, and London, England. Contact 480.422.1810 or visit www.PrismicPharma.com 

INFORMATION CONTACT Peter Moriarty Tel: 480.422.1810

SOURCE Prismic Pharmaceuticals, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs